| 000 | 02839cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031826.0 | ||
| 008 | 171016s2016 ua f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.33.M.Sc.2016.Yo.R | ||
| 100 | 0 | _aYomna Mohamed Mostafa Hasan | |
| 245 | 1 | 0 |
_aRole of novel proteomic markers (apolipoprotein A1 and apolipoprotein A4) in early detection of HCC in chronic HCV infected patients / _cYomna Mohamed Mostafa Hasan ; Supervised Hasan Ahmed Ali Elgarem , Hanan Hasan Fouad , Rabab Maamoun Salama |
| 246 | 1 | 5 | _aدور الدلالات البروتيومية الحديثة (أبوليبوبروتين أ1 و أبوليبوبروتين أ4) فى الكشف المبكر لأورام الكبد فى مرضى الالتهاب الكبدى الفيروسى المزمن سى |
| 260 |
_aCairo : _bYomna Mohamed Mostafa Hasan , _c2016 |
||
| 300 |
_a123 P. ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine | ||
| 520 | _aBackground: HCC is one of the leading causes of cancer-related deaths worldwide and the poor survival rate is largely due to late stage diagnosis. Novel proteomic markers Apo-A1 and Apo-A4 can be used in combination with other traditional markers such as AFP for an earlier and more efficient diagnosis of HCC. Aim of the work: This study was designed to detect the role of novoe proteomic markers in early detection of HCC; Apo-A1 and Apo-A4 using ELISA technique. Methods: Plasma samples were obtained from 20 HCC patients, 20 HCV-related liver cirrhosis and 20 chronic HCV patients in addition to 20 seronegative controls. Routine clinical, laboratory and ultrasonographic assessments were done. HCC was diagnosed according to AASLD (the American association for the Study of Liver Diseases) guidelines. ELISA technique was used to detect Apo-A1 and Apo-A4. RESULTS: Increased levels of Apo-A1 in HCC patients and chronic liver patients post HCV with significant difference. Decreased levels of Apo-A4 in HCC patients, Relative increase of Apo-A4 levels in chronic liver patients. Thus Apo-A1is more specific in early detection of HCC with specificity (97.5%). Concluson: Apo-A1 can be used in early detection of HCC in Chronic liver patients post HCV infection and it is more specific than Apo-A4 | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aApo-A1 and Apo-A4 | |
| 653 | 4 | _aHepatocellular carcinoma | |
| 653 | 4 | _aProteomic markers | |
| 700 | 0 |
_aHanan Hasan Fouad , _eSupervisor |
|
| 700 | 0 |
_aHasan Ahmed Ali Elgarem , _eSupervisor |
|
| 700 | 0 |
_aRabab Maamoun Salama , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c62981 _d62981 |
||